Related posts

TSX hits high, Wall Street flatMild gains and lossesMild Monday
Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

ResMed Inc., trading under the symbol RMD-N, has positioned itself as a leader in the sleep apnea treatment market, commanding an impressive 90% market share. The growing awareness of sleep disorders, amplified by gadgets like the Google Watch, has generated a rising demand for sleep apnea machines, which bodes well for ResMed's growth trajectories. Despite recent fluctuations in share prices, analysts remain optimistic about ResMed's potential, underscored by strong management and strategic positioning within a burgeoning industry. With a projected price target of $241.48, experts believe the company has solid fundamentals and the capability to rebound from recent lows.

Consensus
Positive
Valuation
Undervalued
TOP PICK

Gagdets like Goggle Watch have shown people how poorly they sleep. Resmed makes sleep apnea machines, which sees big, growing demand, and they hold 90% of the market.

(Analysts’ price target is $241.48)
BUY ON WEAKNESS

Shares have been knocked down. Good management.

BUY
They make sleep apnea machines, but now make ventilators during quarter. Last-October they just reported a super quarter that pushed the stock from $180 to $220 in days. It's pulled back to $211 because of positive vaccine news. It'll get a boost from their sleep apnea machines after Covid when people will visit their doctors again.
PAST TOP PICK
(A Top Pick Sep 25/18, Up 18%) They had a big correction in January and he got stopped out. Pity, because he missed that big run after January. We work on sleep apnea devices, which is a demographic play. A great name. Wishes he still owned it.
TOP PICK

18 million Americans have sleep apnea with many others undiagnosed. They have 2.5 billion nights of medical sleep data. They take cases out of hospitals and into homes. Based in Australia and the U.S. Shares have been been steadily rising. (1.3% dividend yield, Analysts' price target $109.75)

PAST TOP PICK

(A Top Pick May 13/16. Up 30.65%.) The leader in sleep apnea, and primarily manufactures the masks. Recently sold his holdings.

PAST TOP PICK

(A Top Pick Feb 11/16. Up 24%. Up 24%.) Sleep apnea is such an unaware market. 26% of the population have it, and the penetration is less than 15%. Last year, there was a lot of built-up demand for the masks that they create, because the new line was being rolled out. They’ve rolled out the new masks, and there has been more demand than had been expected. The dividend is just under 2%. He is continuing to buy this.

PAST TOP PICK

(A Top Pick Jan 11/16. Up 33.32%.) This company deals with sleep apnea by providing masks and devices. The opportunity on this is that they are very close to a refresh cycle with their masks, and there is some pent-up demand waiting for the new models to come out.

TOP PICK

This deals with sleep apnea by producing the mask and the device that helps deliver the oxygen. 26% of adults suffer from sleep apnea. In developed markets it has only about 10%-15% penetration, and in emerging markets only 5%, so he likes the upside. Dividend yield of 2.09%.

WATCH

Some of the shareholders are super bright buys. They have a good shareholder base. They had a bit of a failure to launch. They don’t have a long shelf life. You have a more activist board that are shaking the tree. It is going to have prospects. He wants to see something happen with their capital.

TOP PICK

Sleep Apnea. It is quite prevalent – 25% of the population have it. 2.12% dividend. It is the leader to provide the devices.

TOP PICK

They address sleep apnea. It affects many more people than we think. Many have it and are not aware of it. They are the leader in the space. They build the machine and the custom mask. It is a space that is very much underpenetrated. He sees growth in the share price.

Showing 1 to 12 of 12 entries
  • «
  • 1
  • »

ResMed Inc.(RMD-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for ResMed Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

ResMed Inc.(RMD-N) Frequently Asked Questions

What is ResMed Inc. stock symbol?

ResMed Inc. is a American stock, trading under the symbol RMD-N on the New York Stock Exchange (RMD). It is usually referred to as NYSE:RMD or RMD-N

Is ResMed Inc. a buy or a sell?

In the last year, 1 stock analyst published opinions about RMD-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for ResMed Inc..

Is ResMed Inc. a good investment or a top pick?

ResMed Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for ResMed Inc..

Why is ResMed Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is ResMed Inc. worth watching?

1 stock analyst on Stockchase covered ResMed Inc. In the last year. It is a trending stock that is worth watching.

What is ResMed Inc. stock price?

On 2025-03-14, ResMed Inc. (RMD-N) stock closed at a price of $222.84.